Achieving ASDAS Inactive Disease Status in Axial Spondyloarthritis in Clinical Trials: A Systematic Review and Meta-analysis

This study demonstrates that attainment of ASDAS inactive disease in axSpA clinical trials is consistently low, reflecting the stringency of this remission threshold within trial designs. These findings underscore the importance of interpreting ASDAS-ID alongside ASDAS-LDA, which may represent a more attainable and clinically meaningful disease state when remission is not achieved.